programmed death receptor-1

临床试验

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

计划入组 315 人 · 首次发布于 2019 年 10 月 16 日

招募中

NCT06031636

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

计划入组 15 人 · 首次发布于 2023 年 9 月 11 日

已完成

NCT05337267

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

计划入组 117 人 · 首次发布于 2022 年 4 月 20 日

药物

查看全部 8226 →

Biotech

Approved

Cemiplimab(Libtayo)

相关疾病：Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma，另有 6 项

death receptor 5 agonist

Programmed cell death 1 antibody(Sun Yat-Sen University)

机构

查看全部 1413 →

Arvinas Estrogen Receptor, Inc.

United States

NHI-1

United States

Arvinas Androgen Receptor, Inc.

United States

资讯

查看全部 18929 →

去年

Ultimovacs' Phase II FOCUS Trial of UV1 in Head and Neck Cancer Fails to Meet Endpoints

去年

GSK Launches First PD-1 Immunotherapy and PARP Inhibitor for Gynecological Cancers in India

去年

临床试验

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

药物

Cemiplimab(Libtayo)

death receptor 5 agonist

Programmed cell death 1 antibody(Sun Yat-Sen University)

机构

Arvinas Estrogen Receptor, Inc.

NHI-1

Arvinas Androgen Receptor, Inc.

资讯

Ultimovacs' Phase II FOCUS Trial of UV1 in Head and Neck Cancer Fails to Meet Endpoints

GSK Launches First PD-1 Immunotherapy and PARP Inhibitor for Gynecological Cancers in India

Subcutaneous Pembrolizumab Meets Primary Endpoints in Phase 3 NSCLC Trial